Advertisement

Topics

FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma

07:00 EST 1 Dec 2016 | Merck & Co., Inc.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more

Original Article: FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...